About diamedica therapeutics inc - DMAC
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
DMAC At a Glance
DiaMedica Therapeutics, Inc.
301 Carlson Parkway
Minneapolis, Minnesota 55305
| Phone | 1-763-496-5454 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -24,444,000.00 | |
| Sector | Health Technology | Employees | 28 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
DMAC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.71 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.591 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
DMAC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -873,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
DMAC Liquidity
| Current Ratio | 8.276 |
| Quick Ratio | 8.276 |
| Cash Ratio | 8.191 |
DMAC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -48.642 |
| Return on Equity | -53.269 |
| Return on Total Capital | -59.535 |
| Return on Invested Capital | -52.95 |
DMAC Capital Structure
| Total Debt to Total Equity | 0.835 |
| Total Debt to Total Capital | 0.828 |
| Total Debt to Total Assets | 0.734 |
| Long-Term Debt to Equity | 0.582 |
| Long-Term Debt to Total Capital | 0.577 |